Razvitie BioTekhnologiy

Razvitie BioTekhnologiy (RBT) is a Russian biotechnology company specializing in the development of innovative vaccines and immunobiological preparations. As a subsidiary of Artgen Biotech, the company utilizes its proprietary 'Betusphere' platform, which leverages a natural betulin-based corpuscular adjuvant to enhance the efficacy and safety of subunit vaccines. RBT's lead programs include the Betuvax-CoV-2 vaccine for COVID-19 and the TetraFluBet quadrivalent influenza vaccine, both of which have advanced into clinical trials. The company is also expanding its pipeline to address high-need areas such as HPV, rotavirus, and RSV, while also exploring veterinary applications and medical devices. Headquartered in Moscow and a resident of the Skolkovo Innovation Center, RBT maintains manufacturing facilities in the Perm region and is actively preparing for a planned IPO in 2026.